11 mei 2017

|  |  |  |
| --- | --- | --- |
| **TIME** | **MEETING HALL A** |  |
| 08:30 – 10:00 | **ACUTE MYELOID LEUKEMIA** Scientific Chairs: **Jacob Rowe (Shaare Zedek Medical Center, Jerusalem, Israel), Siret Ratip (Acıbadem Kozyatagi Hospital, Istanbul, Turkey)**   * Novel Agents in AML: **Eytan Stein (Memorial Sloan Kettering Cancer Center, New York, USA)** * Transplants for AML in First Complete Remission: **Nicolaus Kröger (University Medical Center Hamburg-Eppendorf, Hamburg, Germany)** * Importance of MRD in AML: **Jacob Rowe (Shaare Zedek Medical Center, Jerusalem, Israel)** |  |
| 10:00 – 10:30 | **COFFEE BREAK** |  |
| 10:30 – 12:00 | **MULTIPLE MYELOMA** Scientific Chairs: **Evangelos Terpos (University of Athens School of Medicine,Alexandra General Hospital, Athens, Greece), Güner Hayri Özsan (Dokuz Eylül University, Izmir, Turkey)**   * Optimal Therapy for Newly Diagnosed Patients Who Are Eligible for Autologous Transplantation:**Evangelos Terpos (University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece)** * Can MRD Tailor Therapy for Myeloma Patients? : **C. Ola Landgren (Memorial Sloan Kettering Cancer Center, New York, USA)** * Emerging Problems with the Use of Monoclonal Antibodies in the Everyday Management of Myeloma Patients: **Efstathios Kastritis (National and Kapodistrian University of Athens School of Medicine, Athens, Greece)** |  |
| 12:00 – 13:15 | **LUNCH** | **POSTER DISCUSSION** |
| 13:15 – 14:15 | **SATELLITE SYMPOSIUM http://icllm2017.org/wp-content/uploads/2017/01/amgen-300x77.png**  Scientific Chair: **Ali Zahit Bolaman (Adnan Menderes University, Aydın, Turkey)**  New Era in the Treatment of Relapsed / Refractory Multiple Myeloma: **Evangelos Terpos (University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece)** |  |
| 14:15 – 14:30 | **BREAK** |  |
| 14:30 – 16:00 | **DIFFUSE LARGE B-CELL LYMPHOMA** Scientific Chairs:**Christian Gisselbrecht (Hospital Saint Louis, Paris, France), Levent Ündar (Akdeniz University, Antalya, Turkey)**   * Update on Pathology  with  New WHO Classification: **Thierry Jo Molina (Necker University Hospital, Paris, France)** * Relapse DLBCL Where Are We With ASCT?: **Christian Gisselbrecht (Hospital Saint Louis, Paris, France)** |  |
| 16:00 – 16:30 | **COFFEE BREAK** |  |
| 16:30 – 17:30 | **BCR/ABL NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS** Scientific Chairs:**Francesca Palandri (University of Bologna, Italy), Fahir Özkalemkaş (Uludag University, Bursa, Turkey)**   * Philadelphia – Negative Chronic Myeloproliferative Neoplasms: Diagnostic Criteria and Personalized Therapy in 2017: **Francesca Palandri (University of Bologna, Italy)** |  |
| 18:00 – 19:30 | **OPENING CEREMONY** |  |

12 mei 2017

|  |  |  |
| --- | --- | --- |
| **TIME** | **MEETING HALL A** |  |
| 09:00 – 10:00 | **ACUTE LYMPHOBLASTIC LEUKEMIA**  Scientific Chair:**Monique den Boer (Erasmus University Medical Center, Rotterdam, The Netherlands), Hale Ören (Dokuz Eylül University, Izmir, Turkey)**   * New Prognostic and Predictive Markers for ALL: **Monique den Boer (Erasmus University Medical Center, Rotterdam, The Netherlands)** * Treatment of Young Adult ALL: **İnci Alacacıoğlu (Dokuz Eylül University, İzmir, Turkey)** |  |
| 10:00 – 10:30 | **COFFEE BREAK** |  |
| 10:30 – 11:30 | **SATELLITE SYMPOSIUMhttp://icllm2017.org/wp-content/uploads/2016/05/bms-300x40.png**  Scientific Chairs:**Mustafa Çetin (Erciyes University, Kayseri, Turkey), Mustafa Nuri Yenerel (İstanbul University, İstanbul, Turkey)**  The Impact of Dasatinib on Clinical Management and Pathobiology of CML: **İbrahim C. Haznedaroğlu (Hacettepe University, Ankara, Turkey)** |  |
| 11:30 – 11:45 | **BREAK** |  |
| 11:45 – 13:15 | **HODGKIN LYMPHOMA**  Scientific Chairs: **Peter Borchmann (Klinik I für Innere Medizin, Cologne, Germany), Muhit Özcan (Ankara University, Ankara, Turkey)**   * First Line Therapy of Early Stage cHL: Should We Go for PET Adapted Treatment Strategies?:**Veronika Bachanova (University of Minnesota, Minnesota, USA)** * First Line Therapy of Advanced Stage cHL: Pros and Cons for Different Treatment Strategies: **Peter Borchmann (Klinik I für Innere Medizin, Cologne, Germany)** * Relapsed cHL and Perspectives: Will Immunotherapy Replace Chemotherapy?:**Michael Crump (Princess Margaret Cancer Center, University Health Network, Toronto, Canada)** |  |
| 13:15 – 14:30 | **LUNCH** | **POSTER DISCUSSION** |
| 14:30 – 16:00 | **MEETING THE CHALLENGE OF EMERGING PATHOGENS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: ADVANCES IN DIAGNOSIS, TREATMENT, AND PREVENTION**  Scientific Chairs:**Thomas J. Walsh (Weill Cornell Medicine of Cornell University, New York, USA), Ali Zahit Bolaman (Adnan Menderes University, Aydın, Turkey)**   * Multidrug Resistant Bacterial Infections in Patients with Hematological Malignancies: New Compounds for Emerging Pathogens: **Thomas J. Walsh (Weill Cornell Medicine of Cornell University, New York, USA)** * Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies: **Maria N. Gamaletsou (St James’s University Hospital, Leeds Teaching Hospitals, Leeds, United Kingdom)** * Viral Infections in Patients with Hematological Malignancies: Rapid Molecular Diagnosis and Antiviral Strategies: **Nikolaos V. Sipsas (National and Kapodistrian University of Athens, Athens, Greece)** |  |
| 16:00 – 16:30 | **COFFEE BREAK** |  |
| 16:30 – 17:30 | **MYELODYSPLASTIC SYNDROMES**  Scientific Chairs:**H. Joachim Deeg (Fred Hutchinson Cancer Research Center, Seattle, USA), Zafer Gülbaş (Anadolu Medical Center, Kocaeli, Turkey)**   * Focus on Medical Management of Patients with MDS: **Ibrahim** **Yakoub Agha (Regional University Hospital, Lille, France)** * Focus on Transplantation for MDS: **H. Joachim Deeg (Seattle Cancer Care Alliance, Seattle, USA)** |  |
| 17:45 – 18:45 | **UYDU SEMPOZYUM http://icllm2017.org/wp-content/uploads/2017/01/gilead.png**    Oturum Başkanları: **Sevgi Beşışık (İstanbul Üniversitesi, İstanbul), Fahir Özkalemkaş (Uludağ Üniversitesi, Bursa)**   * Hoşgeldiniz ve Açılış Yorumları: **Sevgi Beşışık (İstanbul Üniversitesi, İstanbul)** * İnvazif Mikozların Değişen Epidemiyoloji: **Sevgi Beşışık (İstanbul Üniversitesi, İstanbul)** * IFI Hastalarındaki Risk Sınıflandırması: **Fahir Özkalemkaş (Uludağ Üniversitesi, Bursa)** | **UYDU SEMPOZYUM http://icllm2017.org/wp-content/uploads/2017/01/gilead.png**    Oturum Başkanları: **Sevgi Beşışık (İstanbul Üniversitesi, İstanbul), Fahir Özkalemkaş (Uludağ Üniversitesi, Bursa)**   * Hoşgeldiniz ve Açılış Yorumları: **Sevgi Beşışık (İstanbul Üniversitesi, İstanbul)** * İnvazif Mikozların Değişen Epidemiyoloji: **Sevgi Beşışık (İstanbul Üniversitesi, İstanbul)** * IFI Hastalarındaki Risk Sınıflandırması: **Fahir Özkalemkaş (Uludağ Üniversitesi, Bursa)** |

13 mei

|  |  |  |
| --- | --- | --- |
| **TIME** | **MEETING HALL A** | **MEET THE EXPERT HALL** |
| 08:30 – 10:00 | **FOLLICULAR LYMPHOMA**  Scientific Chairs: **Massimo Federico (Università degli Studi di Modena e Reggio Emilia, Modena, Italy), Burhan Ferhanoğlu (Koç University, Istanbul, Turkey)**   * First Line Therapy for Follicular Lymphoma: **Elif Birtaş Ateşoğlu (Kocaeli University, Izmit, Turkey)** * Are We Ready for a Chemofree Approach for Treating Patients with Advanced Follicular Lymphoma?: **Armando Lopez Guillermo (Hospital Clinic of Barcelona, Barcelona, Spain)** * Maintenance Therapy: All Fit in One?:**Massimo Federico (Università degli Studi di Modena e Reggio Emilia, Modena, Italy)** |  |
| 10:00 – 10:30 | **COFFEE BREAK** |  |
| 10:30 – 11:30 | **SATELLITE SYMPOSIUM** http://icllm2017.org/wp-content/uploads/2017/01/celgene.png Scientific Chair: **Yıldız Aydın (İstanbul University, İstanbul, Turkey)**NEW HOPE for RRMM Patients: FOCUS on Efficacy & Safety of IMNOVID: **Meral Beksaç (Ankara University, Ankara, Turkey)** |  |
| 11:30 – 11:45 | **BREAK** |  |
| 11:45 – 13:15 | **CHRONIC MYELOID LEUKEMIA**  Scientific Chairs: **Hanan Hamed (Ain Shams University, Cairo, Egypt), Teoman Soysal (Istanbul University, Istanbul, Turkey)**   * WHO 2016 Diagnostic Criteria of CML; What is Old, What is New?: **Hanan Hamed (Ain Shams University, Cairo, Egypt)** * Current Molecular Monitoring of CML: **Akif Selim Yavuz (Istanbul University, Istanbul, Turkey)** * Current Clinical Management of CML: **İbrahim C. Haznedaroğlu (Hacettepe University, Ankara, Turkey)** |  |
| 13:15 – 14:30 | **LUNCH** | **POSTER DISCUSSION** |
| 14:30 – 16:30 | **CHRONIC LYMPHOCYTIC LEUKEMIA / AGGRESSIVE LYMPHOMAS**  Scientific Chairs: **Oliver Karanfilski (University Clinic for Hematology, Skopje, Macedonia), Önder Arslan (Ankara University, Ankara, Turkey)**   * Prognostic Factors in Newly Diagnosed CLL: **Oliver Karanfilski (University Clinic for Hematology, Skopje, Macedonia)** * First-Line Therapy for CLL as of 2017: **Fatih Demirkan (Dokuz Eylül University, Izmir, Turkey)** * Relapse/Refractory CLL Treatment: **Ioannis Kotsianidis (University Hospital of Alexandroupolis, Alexandroupoli, Greece)** * The Role of Allogeneic Stem Cell Transplantation in the Treatment of Aggressive Lymphomas: **Anna Sureda (Hospital Duran i Reynals, Barcelona, Spain)** |  |